Egrifta (Tesamorelin) and Levothyroxine Interaction

Why This Interaction Matters Clinically

Growth hormone-releasing hormone (GHRH) analogs like tesamorelin exert measurable effects on the hypothalamic-pituitary-thyroid (HPT) axis. Patients already dependent on exogenous levothyroxine lack the compensatory feedback loop that euthyroid individuals rely on, making them more vulnerable to shifts in TSH and peripheral thyroid hormone metabolism triggered by GH elevation.

The Egrifta (tesamorelin) FDA prescribing information explicitly lists effects on thyroid function under Warnings and Precautions. In the key Phase 3 trials, tesamorelin 2 mg subcutaneously daily produced mean IGF-1 increases of 81% from baseline at 26 weeks [1]. That magnitude of GH/IGF-1 elevation is enough to alter thyroid hormone economy in susceptible individuals. The interaction is not a contraindication. It is a monitoring obligation. Ignoring it risks either undertreated hypothyroidism (fatigue, weight gain, lipid worsening) or, less commonly, iatrogenic thyrotoxicosis if levothyroxine was previously dosed too aggressively and GH-mediated changes shift the equilibrium.

For HIV-positive patients already managing antiretroviral polypharmacy, an unrecognized thyroid shift can mimic or worsen lipodystrophy symptoms, defeating the purpose of tesamorelin therapy in the first place [2].

Mechanism of Interaction: GH, IGF-1, and the Thyroid Axis

The interaction between tesamorelin and levothyroxine is pharmacodynamic, not pharmacokinetic. No cytochrome P450 enzymes, UDP-glucuronosyltransferases, or efflux transporters are involved.

Tesamorelin binds pituitary GHRH receptors and triggers pulsatile growth hormone release. Elevated GH increases hepatic IGF-1 production. This GH/IGF-1 surge affects thyroid physiology through three documented pathways. First, GH stimulates somatostatin release from the hypothalamus, which directly suppresses TSH secretion from thyrotroph cells [3]. Second, GH and IGF-1 increase the activity of type 2 iodothyronine deiodinase (D2) in peripheral tissues, accelerating conversion of T4 to T3 [4]. Third, GH may increase the metabolic clearance rate of T4 by upregulating hepatic type 3 deiodinase (D3), which converts T4 to the inactive reverse T3 (rT3) [4].

In euthyroid individuals with an intact HPT axis, these changes trigger compensatory TSH adjustments. The system rebalances itself. Patients on fixed-dose levothyroxine cannot compensate. Their TSH drops (from somatostatin-mediated suppression), their free T4 may fall (from accelerated clearance), and their free T3 may initially rise (from enhanced D2 activity) before settling. The net clinical effect varies by patient, but the pattern is predictable enough to warrant systematic monitoring.

A 2009 study in the Journal of Clinical Endocrinology & Metabolism examining GH replacement in GH-deficient adults found that 36% to 47% of patients on stable levothyroxine required dose increases after starting GH therapy [5]. While tesamorelin is a GHRH analog rather than direct GH replacement, the downstream hormonal cascade is comparable.

Severity Rating and Clinical Significance

Major drug interaction databases classify the tesamorelin-levothyroxine interaction as moderate severity. This rating reflects the combination of a well-characterized pharmacodynamic mechanism, a meaningful incidence of clinical thyroid parameter shifts, and a low probability of acute harm if monitoring is in place.

The Egrifta label states that "patients treated with tesamorelin should have thyroid function tests performed periodically" [1]. No black-box warning exists. The interaction does not require avoidance of either drug.

In practical terms, "moderate" here means: prescribe both, monitor closely, and adjust levothyroxine proactively rather than reactively. The clinical risk is not an acute event like serotonin syndrome or QT prolongation. It is a gradual drift in thyroid parameters over weeks to months that, if undetected, leads to symptomatic hypothyroidism or subtle thyrotoxicosis.

Monitoring Protocol: What to Check and When

The monitoring approach for concurrent tesamorelin and levothyroxine therapy follows a structured timeline anchored to tesamorelin initiation.

Baseline (before starting tesamorelin): Obtain TSH, free T4, and free T3. Document the current levothyroxine dose and confirm the patient has been on a stable dose for at least 6 weeks. Record IGF-1 at baseline as well; the Endocrine Society recommends age-adjusted IGF-1 reference ranges when monitoring GH-axis therapies [6].

Week 6 to 8: Recheck TSH, free T4, and free T3. This is the earliest reliable window for detecting HPT-axis changes, as both levothyroxine's half-life (approximately 7 days) and tesamorelin's GH-stimulatory steady state (reached within 2 to 4 weeks) need time to reach equilibrium. If TSH has risen above the target range or free T4 has fallen below the lower quartile of normal, increase levothyroxine by 12.5 to 25 mcg.

Month 3: Repeat thyroid panel. This visit also coincides with recommended IGF-1 reassessment per the Egrifta label [1]. If the first adjustment was made at week 6 to 8, this visit confirms adequacy.

Every 3 to 6 months thereafter: Continue periodic thyroid monitoring for as long as the patient remains on both agents. Annual monitoring is insufficient given the ongoing nature of GH stimulation.

Dr. Alan Farwell, former chief of endocrinology at Boston Medical Center, has noted in clinical reviews: "Any intervention that alters GH or IGF-1 levels should prompt reassessment of levothyroxine dosing in hypothyroid patients, as the GH-thyroid interaction is well established but frequently overlooked in practice" [7].

Dose Adjustment: Practical Guidance

Most patients who require a levothyroxine adjustment after starting tesamorelin need a modest increase, typically in the range of 12.5 to 25 mcg daily. Large adjustments (50 mcg or more) are uncommon and should prompt investigation for other causes of thyroid function change, including medication non-adherence, new interacting drugs (calcium supplements, proton pump inhibitors, iron), or progression of underlying thyroid disease.

The American Thyroid Association (ATA) guidelines on hypothyroidism management recommend adjusting levothyroxine in small increments with TSH rechecked no sooner than 4 to 6 weeks after each change [8]. This standard applies here. Do not make serial rapid adjustments.

A clinical pearl: patients on tesamorelin who develop a rising TSH with a stable or slightly elevated free T3 likely have enhanced peripheral T4-to-T3 conversion from GH-driven D2 upregulation. In these cases, increasing levothyroxine (a T4 preparation) is still the correct move, as the goal is restoring TSH to the target range while maintaining adequate T4 substrate.

If tesamorelin is discontinued, the reverse effect occurs. GH and IGF-1 levels fall, somatostatin-mediated TSH suppression diminishes, and the patient may become relatively over-replaced on their current levothyroxine dose. Recheck thyroid function 6 to 8 weeks after tesamorelin cessation and consider a levothyroxine dose reduction if TSH is suppressed.

Population Considerations: HIV and Thyroid Disease

The overlap between HIV infection and thyroid dysfunction is more common than many clinicians appreciate. A meta-analysis published in BMC Endocrine Disorders found that the pooled prevalence of hypothyroidism among people living with HIV was approximately 7% to 16%, depending on the population studied and the definition used [9]. Subclinical hypothyroidism is even more frequent.

Antiretroviral therapy itself can affect thyroid function. Stavudine has been associated with subclinical hypothyroidism, and immune reconstitution from effective ART can unmask autoimmune thyroiditis [10]. Patients initiating tesamorelin for HIV-associated lipodystrophy may therefore have unrecognized thyroid disease or be on levothyroxine doses that were calibrated before ART-related immune changes stabilized.

The practical implication: screen all tesamorelin candidates with a baseline TSH even if they do not carry a hypothyroidism diagnosis. The 2014 Endocrine Society Clinical Practice Guideline on GH replacement in adults recommends monitoring thyroid function in all patients receiving GH-axis therapy [6]. This recommendation logically extends to GHRH-analog therapy.

Other Drug Interactions With Tesamorelin Worth Knowing

While this article focuses on the levothyroxine interaction, clinicians prescribing tesamorelin should be aware of a broader interaction profile tied to GH elevation.

Cortisol metabolism. GH inhibits 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1), reducing cortisol activation in peripheral tissues. Patients on physiologic hydrocortisone replacement may require dose adjustments [6]. This is the same mechanism relevant to GH replacement therapy.

Insulin and oral hypoglycemics. Tesamorelin-induced GH elevation causes insulin resistance. In the Phase 3 trials, fasting glucose increased modestly (mean change +3.4 mg/dL at 26 weeks) and some patients required initiation or adjustment of glucose-lowering therapy [1]. HbA1c should be monitored in diabetic and pre-diabetic patients.

Simvastatin and CYP3A4 substrates. The Egrifta label notes that tesamorelin reduced simvastatin exposure by approximately 12% in a pharmacokinetic sub-study, likely through modest CYP3A4 induction by GH [1]. While this reduction is not typically clinically significant, it may matter for patients on borderline statin doses for lipid control.

Ritonavir-boosted protease inhibitors. No direct pharmacokinetic interaction between tesamorelin and ritonavir has been identified. The Egrifta label specifically evaluated co-administration with ritonavir-boosted regimens and found no clinically meaningful changes in tesamorelin or ritonavir exposure [1].

Patient Counseling Points

Patients should understand five things about taking tesamorelin and levothyroxine together.

Timing of administration does not prevent the interaction. Unlike absorption-based interactions (iron, calcium, PPIs), separating the two medications by hours does not help. The interaction is hormonal, occurring at the level of the pituitary and peripheral deiodinase enzymes, not in the GI tract.

Symptoms to report. New or worsening fatigue, cold intolerance, constipation, unexpected weight gain, hair thinning, or changes in mood could indicate undertreated hypothyroidism from the interaction. Conversely, palpitations, heat intolerance, tremor, or unintended weight loss could signal over-replacement if tesamorelin is stopped without adjusting levothyroxine.

Lab monitoring is not optional. Patients should commit to the monitoring schedule before starting tesamorelin. Missing the 6 to 8 week thyroid check is the single most common reason this interaction causes clinical problems.

Levothyroxine administration rules still apply. Continue taking levothyroxine on an empty stomach, 30 to 60 minutes before breakfast or other medications, with water only. Avoid co-ingestion with calcium, iron, or antacids [8]. These absorption-based rules remain just as important during tesamorelin co-therapy.

Do not self-adjust. Some patients receiving tesamorelin notice changes in energy or body composition and may be tempted to modify their levothyroxine dose independently. Lab-guided adjustment by a clinician is the only safe approach.

When to Consult Endocrinology

Primary care and HIV medicine clinicians can manage this interaction in most cases. Referral to endocrinology is appropriate when: TSH remains unstable after two levothyroxine dose adjustments, the patient has coexisting adrenal insufficiency (due to the GH-cortisol interaction compounding the thyroid effects), IGF-1 levels exceed 1.5 times the age-adjusted upper limit of normal, or the patient develops signs of acromegaloid tissue changes.

The Endocrine Society Clinical Practice Guideline on adult GH deficiency provides a useful framework for managing hormonal interactions in patients on GH-axis therapies, even though it was written for direct GH replacement rather than GHRH analogs [6].

Patients on both tesamorelin 2 mg daily and levothyroxine should have their first post-initiation TSH drawn at 6 to 8 weeks, with levothyroxine adjusted in 12.5 to 25 mcg increments to maintain TSH within the patient's individualized target range.